Clinical trials: Tuberculosis, Pulmonary
Tuberculosis, Tuberculosis, Pulmonary
Shortened Regimen for Drug-susceptible TB in Children
While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs.
- Conditions
- Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node, Mycobacterium Tuberculosis
- Trial name
- SMILE-TB (NCT06253715)
- Testing
- Isoniazid, Rifampin, Pyrazinamide
- Where
- 9 sites in India, Indonesia and 5 more
- Volunteers
- 860 people
- Sponsor
- Johns Hopkins University
IPF, Sarcoidosis
Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases
Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and COPD. Similar sampling from healthy controls for comparative data.
- Conditions
- IPF, Sarcoidosis, Tuberculosis, Asthma
- Trial name
- RESPI-SAM (NCT02807025)
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Imperial College Healthcare NHS Trust
Pulmonary Tuberculosis
Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion
The purpose of this study is to evaluate the safety and immunogenicity of ID93 + GLA-SE vaccine when administered to adult pulmonary Tuberculosis (TB) patients, following successful completion of TB treatment with confirmed…
- Trial name
- NCT02465216
- Testing
- ID93 + GLA-SE
- Where
- 3 sites in South Africa
- Volunteers
- 60 people
- Sponsor
- Access to Advanced Health Institute (AAHI)
Tuberculosis, Pulmonary
Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB)
Prospective, randomized, double-blind, multicentre, placebo-controlled clinical phase IIb trial to evaluate efficacy of RUTI® vaccine in DS- (Drug-Sensitive) and MDR-TB (Multidrug-resistant) patients favourably responding to…
- Trial name
- NCT04919239
- Testing
- RUTI®
- Where
- 2 sites in India
- Volunteers
- 140 people
- Sponsor
- Archivel Farma S.L.
Pulmonary Tuberculosis, Tuberculosis Diagnosis
Diagnostic Accuracy of CAD4TB and C-reactive Protein Assay as Triage Tests for Pulmonary Tuberculosis
In the TB TRIAGE+ ACCURACY study, the accuracy of the following products will be determined: CAD4TB (Delft Imaging System, NL), a digital chest x-ray analysis software Afinion CRP assay (Alere Afinion, USA), which detects a…
- Conditions
- Pulmonary Tuberculosis, Tuberculosis Diagnosis, Covid-19, HIV
- Trial name
- TB TRIAGE+ (NCT04666311)
- Testing
- Accuracy of CAD4TB and Afinion CRP assay for pulmonary TB, CAD4COVID+WBC and COVID-19 RDT for SARS-CoV-2 infection
- Where
- 2 sites in Lesotho, South Africa
- Volunteers
- 1,400 people
- Sponsor
- Klaus Reither
Rifampicin-Resistant Pulmonary Tuberculosis Patients
Drug-Drug Interaction and Food Effect of Sudapyridine(WX-081) With Itraconazole and Rifampin in Healthy Chinese Adults
The goal of this clinical trial is to learn how Sudapyridine (WX-081) tablets interact with other drugs and how food intake affects its pharmacokinetics in healthy Chinese adults.
- Trial name
- WX081-DDI (NCT06701136)
- Testing
- Sudapyridine, Itraconazole, Rifampin
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Shanghai Jiatan Pharmatech Co., Ltd
Tuberculosis, Pulmonary
Clinical Evaluation of the Truenat Point-of-care Tuberculosis Diagnostic Test
Consenting adults presenting with signs and symptoms compatible with pulmonary tuberculosis will be interviewed for demographic and medical information, and then will be asked to provide 3-4 expectorated sputum specimens.
- Trial name
- NCT03712709
- Testing
- Truenat MTB
- Where
- 4 sites in Ethiopia, India
- Volunteers
- 1,926 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Infections and Infestations, Pulmonary Tuberculosis
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
This trial is to describe the safety, tolerability and exposure-toxicity relationship of Depazolid given over 16 weeks, in combination with standard-dose Bedaquiline, Delamanid and Moxifloxacin, compared to standard-dose…
- Trial name
- DECODE (NCT04550832)
- Testing
- Delpazolid, Bedaquiline, Delamanid, Moxifloxacin
- Where
- 5 sites in South Africa, Tanzania
- Volunteers
- 76 people
- Sponsor
- LigaChem Biosciences, Inc.
Pulmonary Tuberculosis
Channa Striata and Curcuma Domestica Supplementation in Patients With Active Pulmonary Tuberculosis
This study aims to evaluate the effect of combined supplementation with Channa striata extract and Curcuma domestica rhizome on nutritional status, inflammatory markers, and quality of life in patients with active pulmonary…
- Trial name
- NCT07887724
- Testing
- CHANA STRIATA AND CURCUMA
- Where
- 2 sites in Indonesia
- Volunteers
- 80 people
- Sponsor
- DINA KEUMALA SARI
Lung Diseases, Tuberculosis
Behavioral Interventions for Control of Tuberculosis
To develop and test various educational strategies targeting primarily minority TB-infected adolescents at two health centers in Los Angeles in an experimental design to assess the relative effectiveness on medication adherence…
- Trial name
- NCT00005742
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Sensitive Pulmonary Tuberculosis
Early Bactericidal Activity Safety Pulmonary Tuberculosis Pyrifazimine (TBI-166)
The new drug pyrifazimine (previous name: TBI-166) developed by the Institute of Materia Medica of the Chinese Academy of Medical Sciences which is Beijing Union Pharmaceutical Second Factory relied on is obtained by retaining…
- Trial name
- NCT04670120
- Testing
- Pyrifazimine (TBI-166)
- Where
- 3 sites in China
- Volunteers
- 56 people
- Sponsor
- Beijing Chest Hospital
Tuberculosis, Pulmonary
Impact of Malnutrition on Pharmacokinetic of Rifampicin, Isoniazid, Pyrazinamide and Ethambutol in TB-HIV Co-infected Children (TB-Speed TB-PK)
TB-Speed TB-PK is a cross-sectional PK study of anti-TB treatment nested in the TB-Speed HIV and TB-Speed SAM studies aiming at assessing the impact of malnutrition on PK of rifampicin, isoniazid, pyrazinamide, and ethambutol in…
- Trial name
- NCT04972903
- Where
- 4 sites in Uganda, Zambia
- Volunteers
- 85 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Post-tuberculosis Lung Disease, Tuberculosis (TB)
Pulmonary Rehabilitation Program in Patients With Post-Tuberculosis Lung Disease
Post-tuberculosis lung disease (PTLD) refers to persistent respiratory symptoms, functional limitation, and/or structural or physiological abnormalities after completion of anti-tuberculosis treatment.
- Trial name
- NCT07709507
- Testing
- Individualized Pulmonary Rehabilitation Program, Standard Post-Tuberculosis Care
- Volunteers
- 80 people
- Sponsor
- Filantropia Hospital
Tuberculosis
Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients.
The purpose of the study is to evaluate the efficacy and safety of Mycobacterium w in new lung tuberculosis patients. Mycobacterium w is a strain of bacterium which is being used as vaccine and adjunct drug against leprosy.
- Trial name
- NCT00341328
- Testing
- Intradermal injection of Mycobacterium w
- Where
- 2 sites in India
- Volunteers
- 300 people
- Sponsor
- Ministry of Science and Technology, India
Tuberculosis, Pulmonary
Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)
Tuberculosis (TB) remains the most important infectious disease in the world. A major barrier to tuberculosis control is poor adherence to long-term and complex treatment regimens.
- Trial name
- ORIENT (NCT05401071)
- Testing
- Short Regimen with Rifapentine 10mg/kg, Standardized Regimen, Short Regimen with Rifapentine 15mg/kg
- Where
- 6 sites in China
- Volunteers
- 2,442 people
- Sponsor
- Huashan Hospital
Tuberculosis, Pulmonary
Personalization of AntiTB Treatment: Evaluation of Pharmacological Determinants of Treatment Response
The aim of the study is to investigate the possible correlation of plasma drug concentrations with Time To Positivity (TTP) in liquid culture in patients with active pulmonary multi sensitive TB in the first two weeks of…
- Trial name
- PAT (NCT03416309)
- Where
- Italy
- Volunteers
- 257 people
- Sponsor
- University of Turin, Italy
Tuberculosis, Tuberculosis, Pulmonary
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ169 Formulation
This is a randomized, double-blind, placebo-controlled, single ascending dose study conducted at one study center in Switzerland.
- Trial name
- NCT03423030
- Testing
- PBTZ169 Formulation, PBTZ169 NCP
- Where
- Switzerland
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Innovative Medicines for Tuberculosis
Tuberculosis
PK Study of Anti-TB Drugs
This is a prospective descriptive and pharmacokinetic study will be conducted among newly diagnosed patients registered in the two SMRU TB clinics located on the Thai-Myanmar border.
- Trial name
- NCT02457208
- Testing
- Isoniazid (H), Rifampicin (R), Pyrazinamide (Z)
- Where
- Thailand
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Community Health Nursing Education, Chronic Obstructive Pulmonary Disease
Virtual Reality Cave vs. Simulated Home for Community Nursing Education: A Crossover Trial Comparing Student Competence, Confidence, and Satisfaction
Background and Purpose Community health nursing is essential for providing healthcare to individuals in home and neighborhood settings.
- Conditions
- Community Health Nursing Education, Chronic Obstructive Pulmonary Disease, Pulmonary Tuberculosis
- Trial name
- NCT07595588
- Testing
- VR CAVE Immersive Simulation for Community Health Nursing Education, Traditional Simulated Home Environment for Community Health Nursing Training
- Where
- Hong Kong
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Pulmonary Tuberculosis
A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK
A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial of LCB01-0371.
- Trial name
- NCT02836483
- Testing
- LCB01-0371 800mg, QD, LCB01-0371 400mg, BID, LCB01-0371 800mg, BID
- Where
- South Korea
- Volunteers
- 79 people
- Sponsor
- LigaChem Biosciences, Inc.